LUCSO-1-French pilot study of LUng Cancer Screening with low-dose computed tomography in a smokers population exposed to Occupational lung carcinogens: study protocol

Fleur Delva, François Laurent, Christophe Paris, Milia Belacel, Patrick Brochard, Olivier Bylicki, Christos Chouaïd, Benedicte Clin, Jean-Dominique Dewitte, Véronique Le Denmat, Jean-François Gehanno, Aude Lacourt, Jacques Margery, Catherine Verdun-Esquer, Simone Mathoulin-Pélissier, Jean-Claude Pairon, Fleur Delva, François Laurent, Christophe Paris, Milia Belacel, Patrick Brochard, Olivier Bylicki, Christos Chouaïd, Benedicte Clin, Jean-Dominique Dewitte, Véronique Le Denmat, Jean-François Gehanno, Aude Lacourt, Jacques Margery, Catherine Verdun-Esquer, Simone Mathoulin-Pélissier, Jean-Claude Pairon

Abstract

Introduction: Guidelines concerning the follow-up of subjects occupationally exposed to lung carcinogens, published in France in 2015, recommended the setting up of a trial of low-dose chest CT lung cancer screening in subjects at high risk of lung cancer.

Objective: To evaluate the organisation of low-dose chest CT lung cancer screening in subjects occupationally exposed to lung carcinogens and at high risk of lung cancer.

Methods and analysis: This trial will be conducted in eight French departments by six specialised reference centres (SRCs) in occupational health. In view of the exploratory nature of this trial, it is proposed to test initially the feasibility and acceptability over the first 2 years in only two SRCs then in four other SRCs to evaluate the organisation. The target population is current or former smokers with more than 30 pack-years (who have quit smoking for less than 15 years), currently or previously exposed to International Agency for Research on Cancer group 1 lung carcinogens, and between the ages of 55 and 74 years. The trial will be conducted in the following steps: (1) identification of subjects by a screening invitation letter; (2) evaluation of occupational exposure to lung carcinogens; (3) evaluation of the lung cancer risk level and verification of eligibility; (4) screening procedure: annual chest CT scans performed by specialised centres and (5) follow-up of CT scan abnormalities.

Ethics and dissemination: This protocol study has been approved by the French Committee for the Protection of Persons. The results from this study will be submitted to peer-reviewed journals and reported at suitable national and international meetings.

Trial registration number: NCT03562052; Pre-results.

Keywords: lung neoplasms; mass screening; occupational exposure; tomography scanners, X-ray computed.

Conflict of interest statement

Competing interests: OB declares competing interest with MSD and Astra-Zeneca. VLD declares competing interest with GSK and Pierre Fabre. Other authors declare that they have no competing interest.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Work packages (WP) and specialised reference centre (SRC) organisation for the LUCSO.
Figure 2
Figure 2
Project phases: recruitment and follow-up calendar.
Figure 3
Figure 3
Organisation of lung cancer screening in subjects at high risk of lung cancer in France.

References

    1. International Agency for Research on Cancer. Cancer incidence and mortality worldwide in 2012. Lyon, France: GLOBOCAN, 2012.
    1. Aberle DR, Adams AM, Berg CD, et al. . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395–409. 10.1056/NEJMoa1102873
    1. American Lung Association. Providing guidance on lung cancer screening to patients and physicians. Chicago: American Lung Association, 2012.
    1. Bach PB, Mirkin JN, Oliver TK, et al. . Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307:2418–29. 10.1001/jama.2012.5521
    1. Couraud S, Cortot AB, Greillier L, et al. . From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d’Oncologie de langue francaise (GOLF). Ann Oncol 2013;24:586–97. 10.1093/annonc/mds476
    1. Detterbeck FC, Mazzone PJ, Naidich DP, et al. . Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2013;143:e78S–92. 10.1378/chest.12-2350
    1. Frauenfelder T, Puhan MA, Lazor R, et al. . Early detection of lung cancer: a statement from an expert panel of the Swiss university hospitals on lung cancer screening. Respiration 2014;87:254–64. 10.1159/000357049
    1. Jaklitsch MT, Jacobson FL, Austin JH, et al. . The American association for thoracic surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012;144:33–8. 10.1016/j.jtcvs.2012.05.060
    1. Kauczor HU, Bonomo L, Gaga M, et al. . ESR/ERS white paper on lung cancer screening. Eur Radiol 2015;25:2519–31. 10.1007/s00330-015-3697-0
    1. Roberts H, Walker-Dilks C, Sivjee K, et al. . Screening high-risk populations for lung cancer: guideline recommendations. J Thorac Oncol 2013;8:1232–7. 10.1097/JTO.0b013e31829fd3d5
    1. Vansteenkiste J, Crinò L, Dooms C, et al. . 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014;25:1462–74. 10.1093/annonc/mdu089
    1. Wender R, Fontham ETH, Barrera E, et al. . American cancer society lung cancer screening guidelines. CA: A Cancer Journal for Clinicians 2013;63:106–17. 10.3322/caac.21172
    1. Coureau G, Salmi LR, Etard C, et al. . Low-dose computed tomography screening for lung cancer in populations highly exposed to tobacco: A systematic methodological appraisal of published randomised controlled trials. Eur J Cancer 2016;61:146–56. 10.1016/j.ejca.2016.04.006
    1. van der Aalst CM, Ten Haaf K, de Koning HJ. Lung cancer screening: latest developments and unanswered questions. Lancet Respir Med 2016;4:749–61. 10.1016/S2213-2600(16)30200-4
    1. Ollier M, Chamoux A, Naughton G, et al. . Chest CT scan screening for lung cancer in asbestos occupational exposure: a systematic review and meta-analysis. Chest 2014;145:1339–46.
    1. Delva F, Margery J, Laurent F, et al. . Medical follow-up of workers exposed to lung carcinogens: French evidence-based and pragmatic recommendations. BMC Public Health 2017;17:191 10.1186/s12889-017-4114-1
    1. Haute Autorité de Santé. [Post-professional follow-up after asbestos exposure. Guidelines of the audition commission]. J Radiol 2011;92:461–6. 10.1016/j.jradio.2011.03.016
    1. Callister ME, Baldwin DR, Akram AR, et al. . British thoracic society guidelines for the investigation and management of pulmonary nodules. Thorax 2015;70:ii1–54. 10.1136/thoraxjnl-2015-207168
    1. Oudkerk M, Devaraj A, Vliegenthart R, et al. . European position statement on lung cancer screening. Lancet Oncol 2017;18:e754–66. 10.1016/S1470-2045(17)30861-6
    1. Haute Autorité de Santé. Arrêt de la consommation de tabac: du dépistage individuel au maintien de l’abstinence en premier recours. 2015.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70. 10.1111/j.1600-0447.1983.tb09716.x
    1. Guida F, Papadopoulos A, Menvielle G, et al. . Risk of lung cancer and occupational history: results of a French population-based case-control study, the ICARE study. J Occup Environ Med 2011;53:1068–77. 10.1097/JOM.0b013e318229ab2e
    1. McRonald FE, Yadegarfar G, Baldwin DR, et al. . The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res 2014;7:362–71. 10.1158/1940-6207.CAPR-13-0206
    1. Salmi LR, Coureau G, Bailhache M, et al. . To screen or not to screen: reconciling individual and population perspectives on screening. Mayo Clin Proc 2016;91:1594–605. 10.1016/j.mayocp.2016.07.017

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj